• Ivana Sopek-Merkaš, Nenad Lakušić, Krunoslav Fučkar, Duško Cerovec, and Kristina Marić Bešić.
• 1Krapinske Toplice Special Hospital for Medical Rehabilitation, Krapinske Toplice, Croatia; 2Faculty of Medicine in Osijek, Josip Juraj Strossmayer University of Osijek, Osijek, Croatia; 3Faculty of Dental Medicine and Health in Osijek, Josip Juraj Strossmayer University of Osijek, Osijek, Croatia; 4Zagreb University Hospital Centre, Zagreb, Croatia; 5School of Medicine, University of Zagreb, Zagreb, Croatia.
• Acta Clin Croat. 2022 Feb 1; 60 (3): 540-543.

AbstractAntiplatelet therapy is an integral part of optimal medicamentous therapy in patients with coronary artery disease. The strategy of antiplatelet/anticoagulant therapy is adjusted (combination of drugs, dosing and duration of therapy) depending on the stage of the disease (acute coronary syndrome with percutaneous coronary intervention, chronic coronary syndrome, or coronary surgical revascularization) and comorbidity of each patient (e.g., atrial fibrillation, left ventricular thrombus, etc.). Guidelines and clinical practice in particular are not uniform and specific regarding dual antiplatelet therapy in patients undergoing coronary artery bypass grafting, especially in the setting of chronic coronary syndrome.

13 keywords...

hide…